疫苗生产商Moderna(MRNA.US)夜盘跌7.7%，报38.76美元。消息面上，美国食品药物管理局(FDA)拒绝对Moderna的试验性流感疫苗mRNA-1010展开审查程序，显示美国政府收紧对美国疫苗的监管。Moderna表示，FDA最新决定与此前公司提交申请并开始为mRNA-1010展开三期临床试验前所提供的意见不一致，公司已要求与FDA会面以了解下一步行动。 Moderna补充称，该疫苗先前已获得批准，FDA亦未有发现疫苗有任何具体的安全性及有效性问题，而是对研究设计提出建议，预计FDA的最新决定不会影响公司今年的财务预期，该疫苗最快将于今年底或明年底获得批准，具体时间取决于美国、欧洲、加拿大及澳洲的监管审查。(格隆汇)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.